作者
Adam J Olszewski, Lasse H Jakobsen, Graham P Collins, Kate Cwynarski, Veronika Bachanova, Kristie A Blum, Kirsten M Boughan, Mark Bower, Alessia Dalla Pria, Alexey Danilov, Kevin A David, Catherine Diefenbach, Fredrik Ellin, Narendranath Epperla, Umar Farooq, Tatyana A Feldman, Alina S Gerrie, Deepa Jagadeesh, Manali Kamdar, Reem Karmali, Shireen Kassam, Vaishalee P Kenkre, Nadia Khan, Seo-Hyun Kim, Andreas K Klein, Izidore S Lossos, Matthew A Lunning, Peter Martin, Nicolas Martinez-Calle, Silvia Montoto, Seema Naik, Neil Palmisiano, David Peace, Elizabeth H Phillips, Tycel J Phillips, Craig A Portell, Nishitha Reddy, Anna Santarsieri, Maryam Sarraf Yazdy, Knut B Smeland, Scott E Smith, Stephen D Smith, Suchitra Sundaram, Adam S Zayac, Xiao-Yin Zhang, Catherine Zhu, Chan Y Cheah, Tarec C El-Galaly, Andrew M Evens
发表日期
2021/4/1
期刊
Journal of clinical oncology
卷号
39
期号
10
页码范围
1129-1138
出版商
Wolters Kluwer Health
简介
PURPOSE
Burkitt lymphoma (BL) has unique biology and clinical course but lacks a standardized prognostic model. We developed and validated a novel prognostic index specific for BL to aid risk stratification, interpretation of clinical trials, and targeted development of novel treatment approaches.
METHODS
We derived the BL International Prognostic Index (BL-IPI) from a real-world data set of adult patients with BL treated with immunochemotherapy in the United States between 2009 and 2018, identifying candidate variables that showed the strongest prognostic association with progression-free survival (PFS). The index was validated in an external data set of patients treated in Europe, Canada, and Australia between 2004 and 2019.
RESULTS
In the derivation cohort of 633 patients with BL, age ≥ 40 years, performance status ≥ 2, serum lactate dehydrogenase > 3× upper limit of normal, and CNS involvement …
学术搜索中的文章
AJ Olszewski, LH Jakobsen, GP Collins, K Cwynarski… - Journal of clinical oncology, 2021